A randomized crossover trial finds that formulation, not just dose, determines how much of the hops-derived compound xanthohumol actually reaches the bloodstream.
Formulation scientists have long treated xanthohumol, a prenylated chalcone found in hops (Humulus lupulus), as a compound with more laboratory promise than practical reach: its hydrophobic structure limits how much of it the intestine can absorb.¹
Interest in the compound extends well beyond absorption alone, with preclinical work examining its antioxidant and metabolic activity, though that research remains largely confined to cell and animal models and has not been established in human outcome trials.¹
A new randomized controlled trial, led by researchers at the University of Bonn and published in Molecular Nutrition & Food Research, now offers human pharmacokinetic data on how much the absorption limitation can be addressed through formulation alone.²
"These findings demonstrate why delivery technology matters when working with promising but poorly bioavailable compounds such as xanthohumol," said Danny Hofeditz, director of quality and product innovation at AQUANOVA AG, whose NovaSOL micellar technology was used in the trial. "NovaSOL is designed to address the fundamental solubility and absorption challenges associated with lipophilic ingredients, and this study provides strong human evidence that a micellar formulation can substantially change how xanthohumol is absorbed."³
Twelve healthy men and women each received 4 interventions in randomized order: 86 mg and 172 mg doses of xanthohumol in its native form, and the same 2 doses formulated with micellar solubilization technology.²
At the 172 mg dose, the micellar formulation produced roughly 3.2 times greater total systemic exposure over 24 hours and a peak plasma concentration about 9.5 times higher than native xanthohumol, reaching 2,379 nmol/L compared with 249 nmol/L. Peak concentrations were also reached faster: at the 86 mg dose, about 58 minutes for the micellar formulation versus 148 minutes for native xanthohumol.²
Notably, the 86 mg micellar dose produced roughly 1.5 times greater 24-hour exposure than the 172 mg native dose, half the material, delivering more of it. No sex-based differences in pharmacokinetics were observed.²
The underlying problem is solubility. Xanthohumol's hydrophobic properties restrict its dispersion in the gut, which in turn limits intestinal uptake regardless of how much is administered.¹
Micellar solubilization approaches, including the one used in this trial, aim to work around that limitation without chemically altering the molecule itself, instead incorporating it into micelle structures intended to improve aqueous dispersibility. "Ingredient selection is only 1 part of creating an effective nutritional product," Hofeditz said. "If an active is poorly absorbed in its native state, delivery becomes a critical part of formulation strategy."³
The trial measured exposure, not clinical outcomes, and the researchers themselves note that repeated-dose studies are still needed to establish what, if any, physiological effects accompany sustained xanthohumol intake.²
That distinction matters in a regulatory landscape where xanthohumol-specific claims have already been tested and rejected: in 2018, the European Food Safety Authority's Panel on Dietetic Products, Nutrition and Allergies found that evidence submitted for a xanthohumol-enriched extract did not substantiate a claim of DNA protection against oxidative damage.⁴ Improved absorption is a formulation result, not a health claim, and brands exploring xanthohumol will still need outcome-specific evidence before marketing it on any particular benefit.
References
1. Liu M, Hansen PE, Wang G, et al. Pharmacological profile of xanthohumol, a prenylated flavonoid from hops (Humulus lupulus). Molecules. 2015;20(1):754-779. doi:10.3390/molecules20010754
2. Brehmer-Henkel S, Diekmann C, Eickeler M, et al. The bioavailability of xanthohumol in humans and the influence of formulation and dose: randomized controlled trial data. Mol Nutr Food Res. 2026;70(4):e70413. doi:10.1002/mnfr.70413
3. Human study demonstrates significantly enhanced bioavailability of xanthohumol with AQUANOVA's NovaSOL technology. AQUANOVA AG. October 1, 2026. Accessed October 2, 2026.
4. EFSA Panel on Dietetic Products, Nutrition and Allergies (NDA). Xanthohumol in XERME, a xanthohumol-enriched roasted malt extract, and protection of DNA from oxidative damage: evaluation of a health claim pursuant to Article 13(5) of Regulation (EC) No 1924/2006. EFSA J. 2018;16(3):e05192. doi:10.2903/j.efsa.2018.5192
